Synaptogenix, Inc. (NASDAQ:SNPX) Sees Significant Decline in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 21,800 shares, a decrease of 26.8% from the February 13th total of 29,800 shares. Currently, 1.6% of the company’s stock are sold short. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is presently 1.5 days.

Synaptogenix Stock Up 2.1 %

SNPX stock traded up $0.06 during midday trading on Tuesday, hitting $2.86. The company’s stock had a trading volume of 1,539 shares, compared to its average volume of 30,983. The stock’s 50-day moving average price is $3.09 and its 200 day moving average price is $3.07. Synaptogenix has a 1 year low of $2.32 and a 1 year high of $6.22.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC acquired a new position in Synaptogenix, Inc. (NASDAQ:SNPX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned about 0.80% of Synaptogenix at the end of the most recent quarter. Hedge funds and other institutional investors own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.